Literature DB >> 2126219

Fluvoxamine/pimozide treatment of concurrent Tourette's and obsessive-compulsive disorder.

P L Delgado1, W K Goodman, L H Price, G R Heninger, D S Charney.   

Abstract

A 25-year-old man with a history of Tourette's syndrome presented for treatment of OCD symptoms. Fluvoxamine worsened tics, led to coprolalia, and did not help the OCD. The addition of pimozide dramatically reduced both OCD and Tourette's symptoms. Double-blind sequential discontinuation of fluvoxamine and pimozide confirmed that pimozide alone reduced only tics and the combination of fluvoxamine and pimozide was required for the improvement in OCD. Tics may reflect a subtype of OCD. Some OCD patients unresponsive to a 5-HT reuptake inhibitor alone may benefit from the addition of a dopamine antagonist.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2126219     DOI: 10.1192/bjp.157.5.762

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  10 in total

Review 1.  The biochemistry of Tourette's syndrome.

Authors:  P R Chokka; G B Baker; R A Bornstein; C M de Groot
Journal:  Metab Brain Dis       Date:  1995-06       Impact factor: 3.584

Review 2.  A risk-benefit assessment of drugs used in the management of obsessive-compulsive disorder.

Authors:  L L Carpenter; C J McDougle; C N Epperson; L H Price
Journal:  Drug Saf       Date:  1996-08       Impact factor: 5.606

Review 3.  Gilles de la Tourette syndrome: symptomatic treatment based on evidence.

Authors:  M M Robertson; J S Stern
Journal:  Eur Child Adolesc Psychiatry       Date:  2000       Impact factor: 4.785

Review 4.  Obsessive-complusive disorder: pharmacological treatment.

Authors:  P H Thomsen
Journal:  Eur Child Adolesc Psychiatry       Date:  2000       Impact factor: 4.785

5.  Growth hormone response to apomorphine in obsessive-compulsive disorder.

Authors:  W Pitchot; M Hansenne; A G Moreno; M Ansseau
Journal:  J Psychiatry Neurosci       Date:  1996-11       Impact factor: 6.186

Review 6.  Pharmacological options for the treatment of Tourette's disorder.

Authors:  F J Jiménez-Jiménez; P J García-Ruiz
Journal:  Drugs       Date:  2001       Impact factor: 9.546

7.  Selective serotonin re-uptake inhibitors decrease schedule-induced polydipsia in rats: a potential model for obsessive compulsive disorder.

Authors:  A Woods; C Smith; M Szewczak; R W Dunn; M Cornfeldt; R Corbett
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

Review 8.  Anxiety and affective disorder comorbidity related to serotonin and other neurotransmitter systems: obsessive-compulsive disorder as an example of overlapping clinical and genetic heterogeneity.

Authors:  Dennis L Murphy; Pablo R Moya; Meredith A Fox; Liza M Rubenstein; Jens R Wendland; Kiara R Timpano
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2013-02-25       Impact factor: 6.237

9.  European clinical guidelines for Tourette syndrome and other tic disorders. Part II: pharmacological treatment.

Authors:  Veit Roessner; Kerstin J Plessen; Aribert Rothenberger; Andrea G Ludolph; Renata Rizzo; Liselotte Skov; Gerd Strand; Jeremy S Stern; Cristiano Termine; Pieter J Hoekstra
Journal:  Eur Child Adolesc Psychiatry       Date:  2011-04       Impact factor: 4.785

10.  Pimozide: An Old Wine in a New Bottle!

Authors:  Ahmed Naguy
Journal:  Indian J Psychol Med       Date:  2017 May-Jun
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.